- Home
- CRNX vs MLTX Comparison
CRNX vs MLTX Comparison
Compare CRNX & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- MLTX
- Stock Information
- Founded
- CRNX 2008
- MLTX 2021
- Country
- CRNX United States
- MLTX Switzerland
- Employees
- CRNX N/A
- MLTX N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- MLTX Health Care
- Exchange
- CRNX Nasdaq
- MLTX Nasdaq
- Market Cap
- CRNX 2.8B
- MLTX 2.8B
- IPO Year
- CRNX 2018
- MLTX N/A
- Fundamental
- Price
- CRNX $31.75
- MLTX $49.00
- Analyst Decision
- CRNX Strong Buy
- MLTX Strong Buy
- Analyst Count
- CRNX 8
- MLTX 7
- Target Price
- CRNX $74.86
- MLTX $73.33
- AVG Volume (30 Days)
- CRNX 725.8K
- MLTX 463.2K
- Earning Date
- CRNX 08-07-2025
- MLTX 08-06-2025
- Dividend Yield
- CRNX N/A
- MLTX N/A
- EPS Growth
- CRNX N/A
- MLTX N/A
- EPS
- CRNX N/A
- MLTX N/A
- Revenue
- CRNX $760,000.00
- MLTX N/A
- Revenue This Year
- CRNX $402.02
- MLTX $103.42
- Revenue Next Year
- CRNX $771.03
- MLTX N/A
- P/E Ratio
- CRNX N/A
- MLTX N/A
- Revenue Growth
- CRNX N/A
- MLTX N/A
- 52 Week Low
- CRNX $24.10
- MLTX $31.42
- 52 Week High
- CRNX $62.53
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- CRNX 57.94
- MLTX 63.01
- Support Level
- CRNX $28.98
- MLTX $46.37
- Resistance Level
- CRNX $32.49
- MLTX $49.29
- Average True Range (ATR)
- CRNX 1.24
- MLTX 1.85
- MACD
- CRNX 0.30
- MLTX 0.05
- Stochastic Oscillator
- CRNX 90.54
- MLTX 88.30
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.